Sergio Martinez
Pulmonary Disease · Jackson Heights, NYNPI 1336171040
Payments from drug & device makers
Across 383 payments — averaging $107.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$25K
- AstraZeneca$8K
- AbbVie$2K
- Bayer$2K
- GSK$761
- Amgen$383
- plus $3K from 32 others
What the payments were for
- Speaking & faculty fees$22,03054%
- Travel & lodging$3,0367%
- Food & beverage$15,96039%
- Education$1170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 45 | $25,249 |
| AstraZeneca | 131 | $7,983 |
| AbbVie | 25 | $1,765 |
| Bayer | 41 | $1,510 |
| GSK | 26 | $761 |
| Amgen(2 entities) | 7 | $383 |
| Medtronic | 10 | $348 |
| Boehringer Ingelheim | 9 | $252 |
| Gilead | 9 | $249 |
| Novo Nordisk | 6 | $222 |
| Insmed, Inc. | 10 | $219 |
| Baxter Healthcare | 7 | $187 |
| Abbott | 2 | $177 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $166 |
| Pfizer | 3 | $153 |
| Ironwood Pharmaceuticals, Inc | 1 | $125 |
| Intuity Medical Inc | 1 | $120 |
| Otsuka America Pharmaceutical, Inc. | 5 | $118 |
| Inspire Medical Systems, Inc. | 1 | $112 |
| Mannkind Corporation | 2 | $108 |
| Lilly USA, LLC | 6 | $107 |
| Inogen, Inc. | 6 | $106 |
| Cequr Corporation | 1 | $103 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $97 |
| Actelion Pharmaceuticals US, Inc. | 1 | $79 |
| Viatris Specialty LLC | 2 | $72 |
| Global Blood Therapeutics, Inc. | 3 | $71 |
| Johnson & Johnson(2 entities) | 3 | $60 |
| Mylan Specialty L.p. | 2 | $53 |
| Advanced Respiratory, Inc | 1 | $33 |
| Ardelyx, Inc. | 1 | $25 |
| Novartis | 1 | $20 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| Electromed, Inc. | 2 | $19 |
| Linus Health, Inc. | 1 | $19 |
| Hologic Sales And Service, LLC | 1 | $19 |
| Philips North America LLC | 1 | $16 |
| Lundbeck LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vascepa$24,375
- BREZTRI$2,394
- BEVESPI AEROSPHERE$1,350
- AIRSUPRA$875
- FARXIGA$854
- Creon$750
- LINZESS$471
- TRELEGY ELLIPTA$250
- Repatha$236
- Cobalt$155
- GALLANT$146
- BREZTRI AEROSPHERE$125
- ELIQUIS$125
- Kerendia$125
- ANORO ELLIPTA$124
- FASENRA$123
- Ozempic$122
- Pogo Automatic Blood Glucose Monitoring System$120
- LifeVest$116
- Inspire$112
How this compares
$41,142 in reported general payments places this provider in the 85th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 38 | $555,279 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 693 | $467,361 |
| Breo ElliptaFluticasone/Vilanterol | 693 | $277,036 |
| Tacrolimus | 246 | $182,197 |
| Budesonide ErBudesonide | 47 | $174,493 |
| OzempicSemaglutide | 105 | $140,170 |
| Clemastine Fumarate | 29 | $139,434 |
| KerendiaFinerenone | 197 | $129,474 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 196 | $125,878 |
| JardianceEmpagliflozin | 151 | $116,351 |
| EliquisApixaban | 130 | $102,139 |
| VascepaIcosapent Ethyl | 231 | $99,263 |
| XiidraLifitegrast | 107 | $92,934 |
| JanuviaSitagliptin Phosphate | 105 | $90,850 |
| LinzessLinaclotide | 145 | $89,355 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $761 | $809,9911,571 claims |
| Boehringer IngelheimOfev, Jardiance, Synjardy, Spiriva Respimat | $252 | $766,077323 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort, Lokelma | $7,983 | $271,517460 claims |
| AbbVieLinzess, Restasis, Vraylar | $1,765 | $206,893246 claims |
| Novo NordiskOzempic, Rybelsus | $222 | $200,275133 claims |
| BayerKerendia | $1,510 | $129,474197 claims |
| PfizerEliquis | $153 | $102,139130 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $107 | $84,47463 claims |
| NovartisEntresto | $20 | $67,35692 claims |
| GileadDescovy | $249 | $50,28225 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $118 | $40,85130 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in Jackson Heights
- Linda RogersNew York$7.1M
- Maria PadillaNew York$3.6M
- R WhiteRochester$3.1M
- Juan WisniveskyNew York$3M
- Bushra MinaNew York$2.5M
- Robert KanerNew York$2.3M
- Negin HajizadehGreenport$2M
- Doreen Addrizzo-HarrisNew York$1.9M
- Sherif El BayadiSyracuse$1.9M
- Daniel LachantRochester$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.